Slow Capital Inc. Cuts Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Slow Capital Inc. lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 28.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 61,575 shares of the company’s stock after selling 24,335 shares during the quarter. Slow Capital Inc.’s holdings in CRISPR Therapeutics were worth $2,424,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the fourth quarter worth about $39,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics in the third quarter worth $40,000. Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at about $43,000. Eastern Bank acquired a new position in CRISPR Therapeutics in the third quarter valued at approximately $70,000. Finally, MCF Advisors LLC purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $80,000. 69.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CRSP has been the subject of several recent analyst reports. Chardan Capital reissued a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Bank of America cut their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Barclays lowered their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $78.38.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $41.85 on Tuesday. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $91.10. The firm has a fifty day moving average of $44.19 and a two-hundred day moving average of $47.57. The company has a market cap of $3.57 billion, a P/E ratio of -14.79 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the previous year, the company earned ($1.41) EPS. As a group, equities analysts predict that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.